10 Things Worth Pay...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$3.58 -0.30 | -7.73%
06/04/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 3.88 |
| 52 Week High | 6.37 |
| 52 Week Low | 1.68 |
| Avg. Daily Vol. (Mil) | 0.22 |
| Beta (3 year) | 1.11 |
| Share Related Items | |
| Mkt Cap (Mil) | 82.27 |
| Shares Out (Mil) | 21.20 |
| Float (Mil) | 20.45 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.70 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 329.08 |
| Price/Book | 5.70 |
| Price/Cash Flow | -4.50 |
| Per Share Data | |
| Earnings | -0.91 |
| Sales | 0.01 |
| Book Value | 0.68 |
| Cash Flow | -0.86 |
| Business Summary | |
|---|---|
| CytRx Corporation is a biopharmaceutical research and development company, which is engaged in the development of human therapeutics. | |
| General Information | |
| 11726 San Vicente Boulevard
Suite 650 Los Angeles, CA 90049 |
|
| www.cytrx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 15 | |
| CEO: Steven A. Kriegsman | |
| Short Interest | |
| Current Month (Mil) | 3.64 |
| Previous Month (Mil) | 2.66 |
| Short Interest Ratio (Days) | 21.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -54.80 |
| Return on Investments | -126.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CYTR
- Portfolio NameUser Type
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma - Business Wire 06.04.12 | 08:06 am
- CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206 - Business Wire 06.03.12 | 09:06 am
- CytRx Regains NASDAQ Compliance - Business Wire 06.01.12 | 08:06 am
- CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research - Business Wire 05.29.12 | 08:05 am
- CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer - Business Wire 04.26.12 | 08:04 am
- CytRx Receives NASDAQ Extension - Business Wire 04.23.12 | 08:04 am
- CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology - Business Wire 04.12.12 | 08:04 am
- CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting - Business Wire 03.27.12 | 08:03 am
- CytRx Reports 2011 Financial Results - Business Wire 03.13.12 | 08:03 am
- CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference - Business Wire 03.05.12 | 08:03 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
